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Surgeons are not trained to decipher the pathogenesis of diseases, which they operate on. They 
are used to repair, remove, or replace defective tissues and organs. Yet, we often see typical 
pathomorphological or pathophysiological phenomena, characteristic of a specific disorder 
that can only be observed during surgery. Such patterns would not be recognized easily by 
current imaging techniques, and their visibility would require a living organism. In modern 
terminology, one could call them “surgical biomarkers”. Many disease entities, today, are still 
not completely deciphered regarding initial links of their pathogenesis, despite decades of 
experimental and clinical research. In such disorders, characteristically named “idiopathic”, 
surgical observations may be helpful to clarify disease mechanisms, two of which we offer here 
for one of these disease entities, namely pulmonary hypertension.
Keywords: arteria pulmonalis, pulmonary hypertension, vasa vasorum, vasculitis, autoimmu-
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Pulmonary hypertension (PH) equally affects the heart, the lung, including its extra-
pulmonary great vessels. Cardiothoracic surgeons take care of all three organ systems, in 
children and adults, opposite to their partners in internal medicine or pediatrics. As the 
surgical coauthors of this article have repaired, removed, and replaced hearts, lungs and 
great vessels for many decades, it came to our mind that PH in its terminal stages exhibits 
similar patterns of disease as does atherosclerosis. In lung transplantation for PH, we often 
find macroscopic signs, characteristic for atherosclerosis, e. g. foam cells with lipid depos-
its, wall thickening, endo-luminal thrombosis, calcific plaques, as well as aneurysm for-
mation, which perfectly correspond to severe atherosclerosis in systemic arteries (Fig. 1).
A second observation regards the increase in collateral circulation beyond arterial 
obstructions. In the coronary circulation of the heart, we know adventitial vasa vasorum 
to sprout new arteries in order to bridge an occluded segment of the artery affected, sup-
plying blood to the lumen distal to the occlusion. When operating on acute coronary 
syndromes or in acute aortic dissections, an impressively increased vascularization can be 
seen in the adventitial layer of the respective artery, confined to the site of the culprit lesion 
and mimicking acute localized inflammation. Upon distal incision into the affected artery, 
tremendous amounts of retrograde blood flow occur, especially in cases with chronic, 
complete occlusion. The same finding can be made in PH, especially in long-standing, 
chronic disease. In the lung, vasa vasorum originate from the bronchial arteries [1–3], and 
their tremendous increase in number and size during progression of PH to stages, where 
surgery is required, results in high amounts of back flow from this collateral circulation.
Thus, for the lung transplant surgeon, two characteristic patterns would suggest a 
comparable disease mechanism in PH and in atherosclerosis of systemic arteries, the mac-
roscopic phenotype of vessel wall changes and the rich collateral circulation from adven-
titial vasa vasorum.
A corresponding mechanism between atherosclerosis and PH is also suggested from 
the significant number of clinical disorders, where these pathologic findings occur simul-
taneously in the рulmonary arteries and in large systemic arteries. Among others, this can 
Fig. 1. Foam cells in the intima of small branches of pulmo-
nary arteries in PH, H&E, x 200
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be found in sleep apnea and sickle cell anemia, in Behçet disease, Takayashu arteritis (both 
being autoimmune entities) and in HIV patients, or in systemic autoimmune inflamma-
tory disorders, e. g. scleroderma and lupus [4–6]. Similar bioregulators (e. g. platelet auta-
coids) are involved in pathogenesis of all these entities [7].
But why is the pathogenesis of PH important in surgery? A major issue here is 
the bronchial circulation, which can complicate surgery on the lung in an important 
fashion.
Bronchial arteries in thoracic surgery
PH represents a family of disease entities of which every lung transplant surgeon 
develops mixed feelings with growing experience. Postoperatively, perfusion of the bron-
chial mucosa is compromised at the donor side of the airway anastomosis, since blood 
supply to this segment of the bronchus is secured via collateral flow from the lung paren-
chyma, only.
Thus, in the early days of lung transplantation, when unilateral replacement was 
favored, nearly all patients died postoperatively from dehiscence of this suture line. The 
initially applied immunosuppressive regimen — copied from renal transplantation at 
that time — did reduce the healing properties of this anastomosis to an unacceptable 
degree. Based on the dismal clinical results of these procedures, nearly all clinical pro-
grams were discontinued in the late 1970s. Only a few years later, though, lung trans-
plantation for PH as the underlying disease paved the way to clinical success. Based on 
the poor results after replacing isolated lungs in infectious disease or chronic obstruc-
tive pulmonary disease (COPD), Norman Edward Shumway (1923–2006) and his team 
at Stanford University focused on PH, thus excluding gross infection of the airway by 
the nature of the disease. They also focused on combined heart and lung transplanta-
tion, which includes an airway anastomosis at the tracheal level, where bronchial ar-
tery supply via the coronary arteries is commonly preserved. Thus, selection of patients 
(with PH) and type of surgical procedure allowed for the first successful clinical lung 
transplant procedures. Only later, immunosuppressive protocols became available that 
would allow for adequate healing of the bronchial anastomoses in isolated lung trans-
plants, as well. In terms of healing of the bronchial anastomosis, the bronchial circula-
tion comes as a friend to the surgeon.
But it can also be a foe. In patients with PH, bronchial collateral circulation may 
develop to an extend, where surgical bleeding control becomes impossible. Due to the 
high number of very thin-walled collateral vessels, mostly originating from the descend-
ing thoracic aorta in humans, they may even represent a contraindication to lung trans-
plantation. Additionally, when transplanting lungs for pulmonary vascular disease in a 
bilateral sequential fashion without the heart, the surgeon has to take special care with 
respect to the commonly hypertrophied right ventricle, but also regarding the left heart. 
The left ventricle often presents preoperatively with a restrictive pathogenesis and very 
small diameters due to long-standing low cardiac output.
For many years, therefore, isolated lung transplantations in subjects with severe 
pulmonary vascular disease of any type exhibited far less positive results compared to 
procedures performed in parenchymal lung disease. Today, extracorporeal circulation 
is commonly installed during surgery for right ventricular protection, and extracor-
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poreal membrane oxygenation (ECMO) support may be required for some days after 
the procedure to allow the left ventricle for adaptation to higher cardiac outputs. Thus, 
technically, lung transplantation for PH remains a very demanding procedure for its 
perioperative management, but recently, with the precautions taken, results have been 
comparable to those for other indications [8]. Yet, bleeding from high-flow bronchial 
arteries, surgically called “collateral circulation” during surgery on one side, and poor 
collateral flow to the donor bronchus after surgery remain complications that need to be 
avoided. These “vasa privata”, to use an old, but more precise name for bronchial arter-
ies, are definitely structures representing rather foe than friend for the lung transplant 
surgeon.
The same is true in surgery for chronic pulmonary thromboembolic disease, repre-
senting a second surgical disease within disorders characterized by PH. Compared to re-
section procedures on the lung parenchyma, again a higher surgical risk is seen in pulmo-
nary thromb-endarterectomies, where use of extracorporeal circulation is mandatory. In 
addition, complete arrest of the circulation, including flow from the heart lung machine, 
has to be installed with the patient cooled to a body temperature of below 26° C. Other-
wise, the tremendous amount of retrograde blood flow from the bronchial circulation 
would obscure the operative field, and a precise endarterectomy down to the level of seg-
mental arteries would not be possible.
Next to the poor healing of bronchial anastomoses during transplantation based on 
bronchial artery transection and the massive retrograde flow in pulmonary end-arterecto-
mies, bronchial arteries represent a threat to thoracic surgeons in a third pathophysiologic 
condition. This is PH in subjects presenting with a history of previous surgical interven-
tions in the chest. In addition to massively enlarged bronchial arteries in the hilum of the 
lung, in such cases multiple, thin-walled arteries from the systemic circulation may have 
developed across adhesions between the visceral and the parietal pleural layers. After ex-
perimental ligation of the pulmonary artery in mice, which lack a bronchial circulation, 
large areas of the inner chest wall are seeded with blood vessels [9].
These collateral vessels from the intercostal arteries grow between the two pleural 
layers to deliver oxygen to the ischemic lung. Macroscopically, their appearance resembles 
“plexiform lesions” within the parenchyma of lungs in PH. In humans, their presence 
remains a contraindication to lung transplantation, still today, since many patients have 
bled to death from such collaterals during explantation of their own lungs in the past. The 
memories of such situations from the early times of combined heart and lung transplanta-
tion will be on the surgeon`s mind for a life-time.
Thus, hyperperfusion of the lung via the bronchial circulation, by surgical experi-
ence, reflects a unifying characteristic in all types of PH (see: table 1 below), as defined by 
a recent WHO classification [4]. This includes — yet to a lesser degree — secondary types 
of PH as seen in terminal stages of lung fibrosis, COPD, or generalized inflammatory 
diseases also affecting the pulmonary circulation, e. g. systemic sclerosis. This “surgical 
biomarker” would represent a further characteristic when looking at similar features in 
PH and atherosclerosis in systemic arteries. This is especially true, since we know that 
bronchial arteries do supply the rich network of vasa vasorum in the adventitial layer 
of the pulmonary artery walls [1; 10], which seem to play an important role in vascular 
remodeling of these vessels in PH [11], as do adventitial vasa vasorum in atherosclerosis 
development in systemic arteries [12].
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Table 1. Classification of PH
Pulmonary hypertension




1.2.2. ALK-1, ENG, SMAD9, CAV1, KCNK3
1.2.3. Unknown
1.3. Drug and toxine induced
1.4. Associated with:




1.5. Persistent pulmonary hypertension of the newborn
Pulmonary venooclusive disease (PVOD) / pulmonary capillary hemangiomatosis
2. Pulmonary hypertension due to left heart disease
2.1. Left ventricular systolic dysfunction
2.2. Left ventricular diastolic dysfunction
2.3. Valvular disease
2.4. Congenital / aquired left heart inflow / outflow tract obstruction and congenital cardiomyopathies
3. Pulmonary hypertension due to lung disease and/or hypoxia
3.1. Chronic obstructive pulmonary disease
3.2. Intestinal lung disease
3.3. Other pulmonary disease with mixed restrictive and obstructive pattern
3.4. Sleep-disordered breathing
3.5. Alveolar hypoventilation disorders
3.6. Chronic exposure to high altitude
3.7. Developmental lung diseases
4. Chronic thromboembolic pulmonary hypertension (CTEPH)
5. Pulmonary hypertension with unclear multifactorial mechanisms
5.1. Hematologic disorders: chronic hemolytic anemia, myeloproliferative disorders, splenectomy
5.2. Systemic disorders: sarcoidosis, pulmonary histiocytosis, lymphangioleiomyomatosis
5.3. Metabolic disorders: glycogen storage disease, Gaucher disease, thyroid disorders
5.4. Others: tumoral obstruction, fibrosing mediastinitis, chronic renal failure, segmental PH
* 5th WSPH Nice 2013
** BMPR = Bone morphogenic protein receptor type II; CAV1 = caveolin-1; ENG = endoglin
Remodeling of pulmonary arteries
During surgery, PH cases with chronic pulmonary embolism can be easily distin-
guished from other PH patients. Here, the typical features of wall thickening, arterial dis-
tension and intimal thrombus formation stops at the level of segmental arteries in most 
cases. Surgical removal by thromb-endarterectomy can actually cure the disease without 
organ replacement, a singular phenomenon looking at the entire spectrum of terminal 
PH. All other entities presenting with PH are progressive in nature, not accessible to con-
ventional surgery, and incurable by known medical treatment. Thus, only transplantation 
can assure medium to long-term survival. In these cases, the disease increases in sever-
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ity from central pulmonary arteries towards their peripheral, intrapulmonary branches, 
which is especially true with regard to wall thickening and luminal thrombosis. Here, the 
main pulmonary arteries are often free from thrombosis, yet, a severe increase of wall 
thickness and luminal diameters are present, sometimes triple the dimensions of the do-
nor pulmonary artery in transplantation. Four years ago, the author of this communi-
cation (AH) contributed “Key role of vasa vasorum dysfunction in the pathogenesis of 
atherosclerosis” [14].
In above mentioned article we focused on the role of the adventitial layer on the 
pathobiology of atherosclerotic remodeling processes in systemic arteries, putting empha-
sis especially on the role of the vasa vasorum in the nutrition of the vascular wall. Many 
surgical observations were outlined, supporting the concept. Like for the pathogenesis 
of atherosclerosis, a number of differing concepts have been proposed regarding disease 
initiation and progression in PH. None of them, as written in a recent review article [14] 
would be able to explain the disease process in a comprehensive fashion.
Again based on surgical observations, and again describing the unique pathophysiol-
ogy of vessel wall nutrition via the vasa vasorum in the small pulmonary arteries involved 
in the disease, a similar, comprehensive concept is proposed here.
In describing the pathophysiological process of vascular remodeling in pulmonary 
arteries during disease initiation and progression in PH, this concept would also highlight 
blood vessel wall ischemia as the driving force of vascular remodeling, in line with the 
previous description of the pathophysiology of atherosclerosis of systemic arteries. An 
important question here would be, if the histologic pattern of disease within the small 
pulmonary arteries in PH does support the hypothesis (Table 2).
Vasa vasorum and vessel wall ischemia
In systemic arteries, vasa vasorum commonly originate from their parent vessel at 
sites of branching. As mentioned before, vasa vasorum of pulmomary arteries originate 
from bronchial arteries. Like in systemic arteries, therefore, oxygenated blood from the 
systemic circulation is provided via the adventitial layer to the wall of pulmonary vessels, 
as well. Offspring from the parent vessel would not be efficient, here, since the arteries in 
the lung, of course, transport de-oxygenated blood. In consequence, a fundamental ana-
tomical difference exists between the systemic and the pulmonary artery tree with regard 
to distribution of their vasa vasorum. In the systemic circulation, only large and medium-
sized vessels carry vasa vasorum [15–17], since the thinner walled smaller arteries are 
supplied with nutrients and oxygen by diffusion from the lumen alone. As a consequence 
of the low oxygen content of the blood in lung arteries, even the small, pre-capillary arter-
ies at external diameters equal or below 200 micrometer are dependent on external blood 
supply via vasa vasorum, since oxygen supply via their lumen would be insufficient [18; 
19]. This finds especially true, because these vessels present with a highly muscularized 
medial layer [20; 21], known to require high rates of oxygen supply. In consequence, and 
opposite to systemic arteries, vessel wall ischemia from disturbed or insufficient micro-
circulation via their vasa vasorum may occur in the small, precapillary, muscular arter-
ies in the lung, as well. To our knowledge, this unique physiologic-anatomical difference 
between the systemic and the pulmonary circulation (Fig. 2) has not been appreciated in 
the literature, so far, although existence of vasa vasorum in adventitia of small extrahilar 
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branches of pulmonary arteries has been shown as early as in 1964, when they were re-
vealed in all branches with ≥ 1 mm of diameter [22].
In systemic arteries, the oxygen demand of their vessel wall increases with growth 
during childhood and adolescence, when the blood pressure increases and higher wall 
tension requires an increase in wall thickness. The anatomic response to this physiolog-
ic phenomenon is the establishment of a microcirculation within the blood vessel wall, 
originating from adventitial vasa vasorum, which are practically absent in arteries in the 
newborn.
Similarly proceeds the ontogenesis of vasa vasorum in human pulmonary arteries: 
they penetrated the outer third of the media in pulmonary trunk starting from fourth 
year, and in the distal part of extrahilar pulmonary arterial bed  — from tenth year of 
postnatal life [23].
But, only those arteries can develop atherosclerosis, where vasa vasorum are present 
[24], and in children, Kawasaki disease (an autoimmune entity) remains confined to aor-
tic and coronary artery segments, where vasa vasorum have been developed [25], already.
Postulating the disturbed microcirculation of the small pulmonary arteries to repre-
sent the initiating factor to precipitate PH, we could see two distinct pathophysiological 
mechanisms to be involved in the initial phase of the disease: the increase in oxygen de-
mand or a decreased supply via arterial vasa vasorum. Thus, an imbalance between oxygen 
demand and supply in the wall of pulmonary arteries has to be operative, if the histo-path-
ologic pattern in PH would result from an analogous mechanism as the atherosclerosis in 
systemic arteries.
There are two types of PH, where a discrepancy between oxygen demand and supply 
would occur from increased demand (Fig. 3).
1. Eisenmenger`s syndrome represents one disorder reflecting a pathophysiological 
situation, where oxygen demand increases with growth of vessel wall thickness. 
High shear stress from increased pulmonary blood flow does results from congen-
ital heart disorders including large left to right shunts on the atrial or on the ven-
Fig. 2. Vasa vasorum in adventitia of small branches of 
pulmonary arteries, H&E, x 200
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tricular level. After years to decades, the resulting hypertrophy of the vessel wall 
in small, precapillary pulmonary arteries requires a substantially increased blood 
supply. If this can no longer be compensated by an increased vascularization via 
adventitial vasa vasorum, ischemia of the vessel wall results in histologic changes, 
the stages of which have been well described earlier [26].
2. The most common type of PH results from left heart failure, resulting in increased 
pulmonary venous pressures. In order to maintain an adequate perfusion pressure 
within the pulmonary capillary bed, pulmonary artery pressure has to increase, 
accordingly [26]. As a result, wall thickness increases, as does oxygen demand, 
comparable to systemic arteries during growth of an individual. In consequence, 
ischemia of the wall in pulmonary arteries, small and large, would result, if de 
novo sprouting of adventitial vasa vasorum becomes insufficient.
These subtypes of PH would represent disorders, where increase in vessel wall 
thickness of small and large pulmonary arteries results in an increased oxygen demand 
(Fig. 2). The other types of PH are characterized by a more peripheral initial affection 
of the pulmonary arterial bed, initially. Here, a decrease in vasa vasorum perfusion and 
subsequent ischemia of the vessel wall from decreased oxygen supply is proposed to rep-
resent the key factor in the pathogenesis of PH.
Hypoventilation of pulmonary alveoli (brought in by any reason) causes alveolar 
hypoxia, which automatically provokes vasoconstriction at the zone of poorly ventilat-
ed alveoli. This phenomenon historically was known as von Euler — Lillestrand “reflex” 
[27]. In fact the phenomenon discovered by these Swedish scholars later appeared to be of 
non-neural origin, because both ganglion blockers and lung denervation were unable to 
prevent it. Nevertheless, this is extremely important mechanism redistributing the blood 
Fig. 3. Pathophysiologial conditions resulting in pulmonary artery wall ischemia and subsequent PH
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supply in favor of well-ventilated lung portions in order to maintain ventilation / perfu-
sion (V/P) matching [28]. Although it is very useful for optimization of regional V/P ratio, 
it should not disturb topical variance of this parameter through the lungs. It can be detri-
mental if violates the topical regional border and involves both lungs in global hypoxia, for 
example, in high altitude disease or in pulmonary heart disease. In such cases it provokes 
generalized vasoconstriction in lesser circulation, thus causing PH.
That is a bright example of the general pathology principle earlier coined by 
L. P. Churilov [29] and stating that the balance of local and systemic defensive mechanisms 
is health prerequisite, but their conflict due to trespassing the borders normally limiting 
their spheres of action is always highly pathogenic.
The very mechanism of the hypoxic pulmonary vasoconstriction is still disputable, 
and there are several theories for its explanation, based on quite remarkable research 
achievements of late 20th century. There are hypoxia-sensitive voltage-gated potassium 
channels in pulmonary artery smooth muscle cells, which cause their depolarization in 
response to low local pO2, with activation of calcium influx and vascular spasm [30]. Also, 
transient receptor potential canonical 6 (TRPC6) and vanilloid 4 (TRPV4) channels are 
involved in such direct reaction probably driven by local autacoids [31].
Moreover, there is an assumption that some electrical signal generated in capillary 
endothelial cells of lesser circulation is transmitted via intercellular gaps upstream to-
wards the arteriole smooth muscle cells, thus representing non-neural “electric wire” and 
resulting in local spasm of arterioles. The antagonists of gap junction connexin-40 protein 
can stop this process and attenuate hypoxic vasoconstriction phenomenon [32].
It is obvious that disorder of vasa vasorum function similar to that observed in ath-
erosclerosis can trigger all the above-mentioned mechanisms and establish PH via mecha-
nisms involved in von Euler — Lillestrand phenomenon. “The end result of the above 
mechanisms is increased pulmonary arterial pressure and resistance” [33].
Hypoxic pulmonary vasoconstriction (HPV) appears to represent a key mechanism 
in the initial phase of these PH types. Its regional activation in cases with local alveolar 
hypoxia, e. g. in atelectasis, pneumonia, or COPD, exerts a beneficial effect on the systemic 
oxygen delivery in that intrapulmonary perfusion is matched to regional ventilation. This 
is a defensive role of vasoconstriction in the small pulmonary arteries in areas with alveo-
lar hypoxia, which, as mentioned above, is known since 1946 [27; 34; 35].
But, it is worth to emphasize again that in global alveolar hypoxia, this response might 
occur throughout the entire pulmonary circulation. This has been shown to result in an 
increased pulmonary artery pressure, which is not the case in regional or focal hypoxic 
conditions. HPV is actuated via sensing oxygen tension in vascular smooth muscle cells 
(SMC), located in the medial layer of the pulmonary artery [36]. The circumferential dis-
tribution of SMC within the medial layer will result in circumferential vessel wall con-
traction. Interestingly, this effect uniformly occurs preferably in pre-capillary pulmonary 
arterioles, immediately proximal to their branching into alveolar capillaries [37]. The 
phenomenon of disease initiation at branching sites is also known from atherogenesis in 
systemic arteries [38; 39]. Looking at the potential influence of adventitial vasa vasorum 
in precipitating vascular contraction, again an analogous phenomenon from systemic ar-
teries may be of importance. The influence of vasa vasorum perfusion has been well dem-
onstrated by surgical removal of the adventitia in the ascending aorta, including the ad-
ventitial vasa vasorum [40]. At this anatomic location, loss of the ability to relax, which is 
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the energy-consuming action of SMCs, results in immediate loss of the Windkessel effect 
of the aorta. As a result, an instantaneous increase in systolic, and a decrease in diastolic 
blood pressure can be observed.
Postulating the same mechanism in HPV, a reduction of flow or in oxygen content 
in the vasa vasorum of the small pulmonary arteries has to be assumed. As opposed to 
left heart failure and Eisenmenger`s syndrome, where increased vessel wall thickness is 
present, this effect must be operative in the normal blood vessel wall both in regional 
and in global HPV. Since the effect occurs in the presence of normoxic arterial blood 
in the bronchial arteries, flow reduction in the vasa vasorum of affected pre-capillary 
pulmonary arteries has to be postulated. Intraluminal oxygen pressure is the same in 
vasoconstricted as well as in normally perfused arteries, thus, here luminal hypoxia 
cannot play a part.
This mechanism of insufficient perfusion of the arterial wall via their adventitial vasa 
vasorum would clearly be supported by the histopathologic findings in HPV, but also in 
other types of PH.
In systemic arteries, no atherosclerosis can be seen in arteries that do not carry vasa 
vasorum, like the internal thoracic artery or intramural stretches of epicardial coronary 
arteries. These observations in the systemic circulation clearly underline the importance 
of vasa vasorum in the pathogenesis of PH, as well. Upon experimental obstruction of 
adventitial vasa vasorum in the aorta in dogs, pigs and rabbits, early signs of atheroscle-
rosis are visible within several days [41–44]. In other experiments, this intervention could 
induce formation of arterial aneurysms [40]. 
All characteristics of early and late changes in HPV (Table 2) are inducible in systemic 
arteries upon vessel wall ischemia from disruption of flow in adventitial vasa vasorum. 
These include SMC proliferation, intimal hyperplasia, luminal thrombosis, increase in 
media thickness, plaque formation and aneurysmatic dilatation. Thus, from both, func-
tional observations (vasoconstriction) and from histopathological findings, disease initia-
tion via malfunctioning adventitial vasa vasorum can be suggested to play a key part in 
HPV pathogenesis, as well.
Recently S. Umar et al. showed that human PH is associated with decreased low 
density lipoprotein (LDL) receptor expression in lungs and increased oxidized LDL in 
lungs and blood plasma. Western diet‐fed LDL receptor knockout mice develop PH and 
right ventricular dysfunction, implicating a role for LDL receptor and oxidized lipids in 
pathogenesis of PH [45]. But LDL receptor dysfunction as well as oxidized lipids and 
reactive oxygen species produced in hypoxia — all are key players in atherogenesis also 
[46–48].
To our opinion, a link which may join together all these facets may be related to au-
toimmunity.
Autoimmunity is deeply involved in pathogenesis of atherosclerosis at many points 
[49]. Immunological links of its pathogenesis and immunological approach to its experi-
mental treatment — both are the old but evergreen ideas dated back to pioneering works 
of 1960s by Hungarian pathologists [50]. Autoantibodies against oxidized low-density li-
poproteins (ox-LDL) take part in atherogenesis; moreover, several experimental models of 
atherosclerosis via passive adoptive T cell transfer and / or immunization with autoanti-
gens such as lipoproteins, β2 glycoprotein Ι (β2-GPI) and heat shock proteins (HSP) — all 
witness for autoimmune links of atherogenesis [51]. 
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The atherogenesis is accelerated in those rheumatic diseases accompanied by au-
toimmune vasculitides [52]. But PH also is common in systemic autoimmune diseases 
proceeding with the immunopathological vasculitides [53]. As early as in 1979 V. P. Gor-
bachev documented regular typical presence of the immunopathological vasculitis of vasa 
vasorum in pulmonary arteries of the patients with polyarteritis nodosa, systemic lupus 
erythematosus, systemic scleroderma, and rheumatoid arthritis [54].
Moreover, recently an autoimmune mouse model of PH was obtained [55]. These 
facts and relations make it possible to assume that atherosclerosis and PH, both quite 
often coinciding [56]. may equally result from autoimmune (immunopathological) vas-
culitides of vasa vasorum.
Fig. 4 below demonstrates lymphoid infitration of vasa vasorum in adventitia of small 
branches of pulmonary artery in a case of PH. Similar lymphoid infiltrates are typical for 
target organs in many autoimmune diseases including some autoimmune vasculitides, 
hence this pathomorphological observation may confirm hypothesis.
By the way, analogous close correlation of systemic and pulmonary atherosclerosis and 
hypertensive states has been recently demonstrated in cats in veterinary pathology [57].
In this communication, the pivotal role of vessel wall ischemia within the complex 
pathobiology of PH is described as a unifying concept for disease initiation and progression 
in all types of PH, except those of thromboembolic genesis. No molecular mechanisms are 
detailed, albeit some of them were mentioned and their understanding would be of signifi-
cance, especially with regard to potential drug treatment. We believe, though, that the ma-
jority of these molecular effects come into play, once ischemia of the vessel wall is initiated.
We provided few pathomorphological vitnesses for the existence of vasa vasorum in 
small branches of pulmonary arteries, for their involvement in atherosclerosis and in im-
munopathological processes (Fig. 1–3 above).
Also, additional important histological findings like immunopathological vasculitis 
of vasa vasorum, perivascular inflammation and adventitial sclerosis, as well as the devel-
opment of lymphoid infiltration and plexiform lesions are still considered consequences 
of HPV, but can be among its initiating features. Yet, understanding their mode of genera-
Fig. 4. Focal small lymphoid infiltrates vasa vasorum in 
adventitia of small branches of pulmonary arteries, H&E, x 200
Вестник СПбГУ. Медицина. 2021. Т. 16. Вып. 1 33
tion would undoubtedly add to our current understanding of the concerted mechanism in 
PH initiation and progression, not the least in regenerative attempts to potentially reverse 
the disease.
At this point, we propose a unifying mechanism for disease initiation and progres-
sion in PH by a dysfunctional microcirculation of the pulmonary arteries at the arteriolar 
level. The hypoxic condition could be the result of increasing wall thickness combined 
with an incomplete response in terms of vascularization in terms of angiogenesis of vasa 
vasorum, or primary dysfunction of vasa vasorum of pre-capillary pulmonary arteries. 
Thus we agree with K. J. Dunham-Snary et al., who stated, “Although increased by en-
dothelium-derived vasoconstrictors (e. g., endothelin and thromboxane) and inhibited by 
endothelium-derived vasodilators (e. g., nitric oxide and prostacyclin), the core effector 
mechanism of HPV lies within the pulmonary arteries SMC” [26] …and would add: “and 
their reaction to a disturbed microcirculation”.
For sure, our assumption can be criticized judging upon a puristic standpoint of clas-
sical pathology that atherosclerosis starts from intima and spreads towards adventitia and 
should be strictly distinctive from arteriosclerosis, which, vice versa, takes origin from 
adventitia spreading inwards to intima [58].
To refute this probable criticism, we have to mention that under the influence of the 
recent experience of transplantology and vascular surgery old good classification of arterio-
sclerosis looks more and more inconsistent, and there is a tendency to its re-thinking [59].
And, after all our hypothesis absolutely is not in contradiction with a statement that 
true atherosclerosis starts from the lesion of endothelium and intima. We just put in the 
centre of attention endothelial and intimal changes in vasa vasorum under the influence 
of their (autoimmune / immunopathological?) vasculitis.
This concept leaves many questions unanswered and opens new ones. How does the 
HPV mechanism translate into idiopathic PH, where alveolar hypoxia cannot represent 
the driving force? How does the mechanism acts in a gender — specific manner and in ge-
netically predisposed individuals, like in carriers of BMDR mutation? What is the role of 
shunting between the bronchial artery system and the pulmonary arteries, and the role of 
shunting between pulmonary arteries and veins, physiological phenomena, clearly sepa-
rating pulmonary hemodynamics from the systemic circulation?
Is it possible that autoimmune / immunopathological vasculitis of vasa vasorum as 
a typical universal mechanism contributes into pathogenesis of several nosologically dif-
ferent and previously not associated cardiovascular disorders, like atherosclerosis, dissect-
ing aneurisms, PH, severe COVID-19 and Kawasaki disease (which idea already has been 
coines in our recent article)?
These and other related questions will have to be answered to fully elucidate the 
pathogenesis of PH in its different categories, hopefully allowing for successful medical 
treatment instead of organ transplantation, in the future.
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